Plicamycin | Mithramycin A | CAS#18378-89-7 | DNA and RNA polymerase inhibitor

MedKoo Cat#: 100740 | Name: Plicamycin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Plicamycin, also known as mithramycin or Mithramycin A is a n antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption.

Chemical Structure

Plicamycin

CAS#18378-89-7

Theoretical Analysis

MedKoo Cat#: 100740

Name: Plicamycin

CAS#: 18378-89-7

Chemical Formula: C52H76O24

Exact Mass: 1084.4727

Molecular Weight: 1085.14

Elemental Analysis: C, 57.56; H, 7.06; O, 35.38

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 350.00	2 Weeks
5mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

A 2371; Antibiotic LA 7017; Aureolic Acid; NSC 24559; PA 144; mithramycin; Mithramycin A;

IUPAC/Chemical Name

(2S,3S)-3-((1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl)-2-(((2S,4R,5R,6R)-4-(((2S,4R,5R,6R)-4-(((2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6-(((2S,4R,5R,6R)-4-(((2S,4R,5S,6R)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-8,9-dihydroxy-7-methyl-3,4-dihydroanthracen-1(2H)-one

InChi Key

CFCUWKMKBJTWLW-WZIVUMCRSA-N

InChi Code

InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45-,49+,50+,51-,52+/m1/s1

SMILES Code

O=C1[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@@H](O[C@H]4C[C@](C)(O)[C@H](O)[C@@H](C)O4)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)CC5=C1C(O)=C6C(O)=C(C)C(O[C@H]7C[C@@H](O[C@H]8C[C@@H](O)[C@H](O)[C@@H](C)O8)[C@H](O)[C@@H](C)O7)=CC6=C5

Appearance

solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in water.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in water.

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Mithracin (plicamycin) is a yellow crystalline compound which is produced by a microorganism, Streptomyces plicatus. Mithracin is available in vials as a freeze-dried, sterile preparation for intravenous administration. Each vial contains 2500 mcg (2.5 mg) of Mithracin with 100 mg of mannitol and sufficient disodium phosphate to adjust to pH 7. After reconstitution with sterile water for injection, the solution has a pH of 7. The drug is unstable in acid solutions with a pH below 4. Mithracin is an antineoplastic agent. It has an empirical formula of C52H76O24

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,085.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Portugal J. Mithramycin and its analogs: Molecular features and antitumor action. Pharmacol Ther. 2024 Aug;260:108672. doi: 10.1016/j.pharmthera.2024.108672. Epub 2024 Jun 3. PMID: 38838821. 2: Zou C, Li W, Zhang Y, Feng N, Chen S, Yan L, He Q, Wang K, Li W, Li Y, Wang Y, Xu B, Zhang D. Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation. Sci Adv. 2024 Apr 5;10(14):eadm7098. doi: 10.1126/sciadv.adm7098. Epub 2024 Apr 3. PMID: 38569039; PMCID: PMC10990282. 3: El-Mayet FS, Santos VC, Wijesekera N, Lubbers S, Harrison KS, Sadeghi H, Jones C. Glucocorticoid receptor and specificity protein 1 (Sp1) or Sp3, but not the antibiotic Mithramycin A, stimulates human alphaherpesvirus 1 (HSV-1) replication. Antiviral Res. 2024 May;225:105870. doi: 10.1016/j.antiviral.2024.105870. Epub 2024 Mar 29. PMID: 38556059; PMCID: PMC11109923. 4: Cao C, Xu Q, Zhu Z, Xu M, Wei Y, Lin S, Cheng S, Zhi W, Hong P, Huang X, Lin D, Cao G, Meng Y, Wu P, Peng T, Wei J, Ding W, Huang X, Sung W, Chen G, Ma D, Li G, Wu P. Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer. Cancer Lett. 2024 Apr 28;588:216809. doi: 10.1016/j.canlet.2024.216809. Epub 2024 Mar 11. PMID: 38471646. 5: El-Mayet FS, Jones C. Specificity protein 1 (Sp1) and glucocorticoid receptor (GR) stimulate bovine alphaherpesvirus 1 (BoHV-1) replication and cooperatively transactivate the immediate early transcription unit 1 promoter. J Virol. 2024 Jan 23;98(1):e0143623. doi: 10.1128/jvi.01436-23. Epub 2023 Dec 12. PMID: 38084958; PMCID: PMC10804982. 6: Zurlo M, Gasparello J, Verona M, Papi C, Cosenza LC, Finotti A, Marzaro G, Gambari R. The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells. Exp Cell Res. 2023 Dec 15;433(2):113853. doi: 10.1016/j.yexcr.2023.113853. Epub 2023 Nov 7. PMID: 37944576. 7: Finotti A, Gasparello J, Zuccato C, Cosenza LC, Fabbri E, Bianchi N, Gambari R. Effects of Mithramycin on BCL11A Gene Expression and on the Interaction of the BCL11A Transcriptional Complex to γ-Globin Gene Promoter Sequences. Genes (Basel). 2023 Oct 11;14(10):1927. doi: 10.3390/genes14101927. PMID: 37895276; PMCID: PMC10606601. 8: Jiang S, Deng T, Cheng H, Liu W, Shi D, Yuan J, He Z, Wang W, Chen B, Ma L, Zhang X, Gong P. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. J Exp Clin Cancer Res. 2023 Aug 9;42(1):199. doi: 10.1186/s13046-023-02756-4. PMID: 37553567; PMCID: PMC10411021. 9: Xu Z, Lee MC, Sheehan K, Fujii K, Rabl K, Rader G, Varney S, Sharma M, Eilers H, Kober K, Miaskowski C, Levine JD, Schumacher MA. Chemotherapy for pain: reversing inflammatory and neuropathic pain with the anticancer agent mithramycin A. Pain. 2024 Jan 1;165(1):54-74. doi: 10.1097/j.pain.0000000000002972. Epub 2023 Jun 27. PMID: 37366593; PMCID: PMC10723648. 10: Wu H, Sun Y, Yang J, Gao Z, Shen H, Li M, Wang D, Tang Y. Iron deficiency downregulates ENPEP to promote angiogenesis in liver tumors. J Nutr Biochem. 2023 Jul;117:109357. doi: 10.1016/j.jnutbio.2023.109357. Epub 2023 Apr 20. PMID: 37085059. 11: Estupiñán Ó, Rey V, Tornín J, Murillo D, Gallego B, Huergo C, Blanco-Lorenzo V, Victoria González M, Rodríguez A, Moris F, González J, Ayllón V, Ramos-Mejía V, Bigas A, Rodríguez R. Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling. Biomed Pharmacother. 2023 Jun;162:114627. doi: 10.1016/j.biopha.2023.114627. Epub 2023 Apr 3. PMID: 37018985. 12: Chen DD, Liu B, Wang Y, Jiang M, Shang G, Xue M, Jia X, Lang Y, Zhou G, Zhang F, Peng X, Hu Y. The downregulation of HSP90-controlled CRALBP expression is associated with age-related vision attenuation. FASEB J. 2023 Mar;37(3):e22832. doi: 10.1096/fj.202201608RR. PMID: 36826429. 13: Fan K, Dong Y, Li T, Li Y. Cuproptosis-associated CDKN2A is targeted by plicamycin to regulate the microenvironment in patients with head and neck squamous cell carcinoma. Front Genet. 2023 Jan 9;13:1036408. doi: 10.3389/fgene.2022.1036408. PMID: 36699463; PMCID: PMC9868476. 14: Lin M, Liu X, Zhang X, Wang H, Fang Y, Wu X, Yin A, Yang W, Zhang D, Li M, Zhang L, Ying S. Sp1 Controls the Basal Level of Interleukin-34 Transcription. Immunol Invest. 2023 Feb;52(2):224-240. doi: 10.1080/08820139.2022.2157283. Epub 2022 Dec 23. PMID: 36562687. 15: Ye S, Ballin G, Pérez-Victoria I, Braña AF, Martín J, Reyes F, Salas JA, Méndez C. Combinatorial biosynthesis yields novel hybrid argimycin P alkaloids with diverse scaffolds in Streptomyces argillaceus. Microb Biotechnol. 2022 Dec;15(12):2905-2916. doi: 10.1111/1751-7915.14167. Epub 2022 Nov 8. PMID: 36346129; PMCID: PMC9733639. 16: Bhosale SS, Mandal A, Hou C, McCorkle JR, Schweer D, Hill KS, Subramanian V, Kolesar JM, Tsodikov OV, Rohr J. Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers. ChemMedChem. 2023 Feb 1;18(3):e202200368. doi: 10.1002/cmdc.202200368. Epub 2022 Nov 22. PMID: 36342449; PMCID: PMC9899322. 17: Gong J, Ji Y, Liu X, Zheng Y, Zhen Y. Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression. Biochem Pharmacol. 2022 Mar;197:114894. doi: 10.1016/j.bcp.2021.114894. Epub 2021 Dec 27. PMID: 34968486. 18: Deng J, Tian AL, Pan H, Sauvat A, Leduc M, Liu P, Zhao L, Zhang S, Chen H, Taly V, Laurent-Puig P, Senovilla L, Li Y, Kroemer G, Kepp O. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death Dis. 2021 Oct 21;12(11):978. doi: 10.1038/s41419-021-04270-x. PMID: 34675191; PMCID: PMC8531384. 19: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Cytotoxic Antibiotics. 2021 Sep 10. PMID: 31643644. 20: Estupiñán Ó, Niza E, Bravo I, Rey V, Tornín J, Gallego B, Clemente-Casares P, Moris F, Ocaña A, Blanco-Lorenzo V, Rodríguez-Santamaría M, Vallina-Álvarez A, González MV, Rodríguez A, Hermida-Merino D, Alonso-Moreno C, Rodríguez R. Mithramycin delivery systems to develop effective therapies in sarcomas. J Nanobiotechnology. 2021 Sep 6;19(1):267. doi: 10.1186/s12951-021-01008-x. PMID: 34488783; PMCID: PMC8419920.